A systematic review on the use of deep venous stenting for acute venous thrombosis of the lower limb

Taha, Mohamed A.; Busuttil, Andrew; Bootun, Roshan; Davies, Alun H.

doi:10.1177/0268355518772760

Cited by 23 publications

(14 citation statements)

References 56 publications

(202 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the treatment of IVCS, balloon angioplasty is inadequate for treating the venous system, and therefore stent placement is frequently required. 16 Current evidence has shown that stent placement after AngioJet thrombectomy or CDT in individuals with acute lower extremity DVT accompanied with IVCS is safe, efficacious, and durable. 17,18 Therefore, we performed PTA and stent implantation after thrombus removal at the occlusion and stenosis area of outflow.…”

Section: Discussionmentioning

confidence: 98%

Outcome of AngioJet mechanical thrombus aspiration in the treatment of acute lower extremities deep venous thrombosis

Wang

Shang

et al. 2020

Vascular

View full text Add to dashboard Cite

Objectives The objective of this study was to evaluate the efficacy and safety in patients with acute lower extremity deep venous thrombosis who underwent pharmacomechanical thrombectomy (PMT, AngioJet mechanical thrombus aspiration). Methods In this retrospective, 424 consecutive patients with acute lower extremity deep venous thrombosis from three institutions were enrolled in the study from January 2015 to December 2018. Of these, patients were divided into two groups, AngioJet group ( n = 186) and catheter-directed thrombolysis (CDT) group ( n = 238). Evaluation indexes including limb circumference difference, length of stay (LOS), urokinase dosage, periprocedural complications, follow-up imaging findings and villalta scores were analyzed from the medical records. Results A total of 424 patients diagnosed with acute lower extremity deep venous thrombosis were collected in this study. These patients were categorized into AngioJet group and CDT group. Significant differences were observed between the two groups with respect to the thigh circumference difference (5.32 ± 1.85 cm vs. 4.69 ± 2.15 cm; p = 0.04), calf circumference difference (2.79 ± 1.54 cm vs. 2.35 ± 1.25 cm; p = 0.01), thigh detumescence rate (72.19 ± 19.55% vs. 65.35 ± 17.26%; p = 0.00) and calf detumescence rate (62.79 ± 18.56% vs. 55.75 ± 17.27%; p = 0.00). The mean dose of urokinase in AngioJet group was 95.16 ± 45.89 million IU significantly less than that in the CDT group 293.76 ± 42.71 million IU ( p = 0.00). The overall bleeding complication rate was 9.91% (19 patients in AngioJet group and 23 patients in CDT group), which included three major (0.71%, 3/424) and 39 minor (9.2%,39/424) events. In the AngioJet group, serum creatinine (sCr) concentration and urine erythrocyte from the hemolysis caused by the mechanical process were higher than baseline data at admission ( p = 0.00, p = 0.00). The postoperative red blood cell and hemoglobin in two groups were lower than baseline data ( p = 0.00, p = 0.00). Compared with CDT, AngioJet thrombectomy has significantly lower estimated incidence of PTS in the follow-up. Conclusion AngioJet thrombectomy has stronger clearance ability for acute lower extremity deep venous thrombosis leading to significant reduction in the consumption of hospital resources, total dose of thrombolytic agents, and infusion time, thereby preventing adverse bleeding events, but patients with renal insufficiency should be careful. Ideal short-term and medium-term efficacy and safety are certain.

show abstract

Section: Discussionmentioning

confidence: 98%

Outcome of AngioJet mechanical thrombus aspiration in the treatment of acute lower extremities deep venous thrombosis

Wang

Shang

et al. 2020

Vascular

View full text Add to dashboard Cite

show abstract

“…El tratamiento antiagregante ha demostrado ser seguro y eficaz en pacientes con stent arteriales, pero su efecto en pacientes con stent venosos, con o sin TVP previa, se desconoce. En una revisión realizada en 2018 se observaron grandes diferencias entre diversos estudios a la hora de administrar antiagregante tras la implantación del stent, mientras que en todos los casos se administró terapia anticoagulante [13][14][15] .…”

Section: Discussionunclassified

May-Thurner syndrome, diagnosis and treatment: a case report

Santiago¹,

Gorbea²,

Gaztelu³

et al. 2019

An Sist Sanit Navar

View full text Add to dashboard Cite

show abstract

“…14 Use of antiplatelet agents did not seem to show any significant benefit. 14 Pregnancy in women who have had previous VTE and stenting procedures may need careful consideration. Retrospective data suggest they are not at increased risk of stent occlusion or recurrent VTE during pregnancy or in the postpartum period, 30 but further data are required.…”

Section: Challenges Of Placing Venous Stentsmentioning

confidence: 99%

Role of venous stenting for venous thromboembolism

Breen

2020

Hematology

View full text Add to dashboard Cite

Endovenous stenting has emerged as the method of choice to treat iliofemoral venous outflow obstruction. It is used in patients with established postthrombotic syndrome (PTS) after previous deep vein thrombosis (DVT) to reduce symptoms of chronic pain and swelling and to aid ulcer healing in severe cases. Venous stenting is used to alleviate symptoms of obstruction in patients presenting with acute DVT, with the aim of preventing development of PTS. There is a low risk of morbidity and mortality associated with the use of endovenous stenting, and although significant advances have been made, particularly improvements in stent design for use in the venous circulation, data are lacking on beneficial long-term outcomes. Unmet research needs include optimal patient selection, anticoagulant choice and duration, best practice for postoperative surveillance, and use of validated assessment tools to measure outcomes. In this article, I address the potential benefits, as well as the challenges, of endovenous stenting.

show abstract

A systematic review on the use of deep venous stenting for acute venous thrombosis of the lower limb

Cited by 23 publications

References 56 publications

Outcome of AngioJet mechanical thrombus aspiration in the treatment of acute lower extremities deep venous thrombosis

Outcome of AngioJet mechanical thrombus aspiration in the treatment of acute lower extremities deep venous thrombosis

May-Thurner syndrome, diagnosis and treatment: a case report

Role of venous stenting for venous thromboembolism

Contact Info

Product

Resources

About